Status:
COMPLETED
Liposomal Bupivacaine for Post-operative Pain Control in Adolescent Bariatric Patients
Lead Sponsor:
Virginia Commonwealth University
Conditions:
Bariatric Surgery Candidate
Post-operative Pain
Eligibility:
All Genders
13-18 years
Phase:
PHASE1
Brief Summary
Liposomal bupivacaine (trade name Exparel) is a local analgesic that is designed to produce more long-term pain control. Bupivacaine, a widely used local analgesic, is stored within liposomes, which b...
Detailed Description
Use of liposomal bupivacaine has not been reported specifically for use in adolescent bariatric surgery. Our rationale is based on the notion that for most minimally invasive procedures, methods curre...
Eligibility Criteria
Inclusion
- patients who are undergoing a laparoscopic sleeve gastrectomy for severe obesity who are between 13 and 2018 years of age.
- Only patients treated at the Children's Hospital of Richmond at VCU will be included.
Exclusion
- patients less than 13 or greater than 2018 years of age
- patients with an allergy to bupivacaine
- any patients undergoing any additional procedures at the time of the laparoscopic sleeve gastrectomy.
- English or Spanish proficiency will be necessary.
Key Trial Info
Start Date :
January 31 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 20 2024
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT06077214
Start Date
January 31 2023
End Date
August 20 2024
Last Update
March 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virginia Commonwealth University
Richmond, Virginia, United States, 23298